…
Binovi Technologies Corp. engages in the development, manufacturing, and commercialization of visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders in Canada, the United States, and internationally. The company's products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete's vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company's products under development includes Binovi Connect, a web-based video conferencing solution that connects consumers to vision care professionals. Binovi Technologies Corp. was formerly known as Eyecarrot Innovations Corp. and changed its name to Binovi Technologies Corp. in June 2020. The company was incorporated in 2011 and is based in Oakville, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Binovi Technologies Corp is an OTC Pink–listed small-cap with limited public disclosures; available materials suggest involvement in vision-performance and digital-health activities. Long-term growth drivers may include rising telehealth adoption and aging-population demand for vision and rehabilitation tools, and investors may find exposure to niche health-technology initiatives appealing if the company can validate product-market fit.
Key risks are sparse financial and operational transparency, low liquidity on the OTC Pink market, an unclear revenue and profitability record, and material execution and financing risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Income before tax | -16.38M | -9.03M | -7.69M | -4.77M | -2.71M |
| Net income | -16.38M | -9.03M | -7.69M | -4.77M | -2.71M |
| Selling general administrative | 3.27M | 5.34M | 6.02M | 3.69M | 2.42M |
| Selling and marketing expenses | 0.81M | 2.11M | 0.49M | 0.37M | - |
| Gross profit | 0.13M | 0.52M | 0.59M | 0.38M | 0.09M |
| Reconciled depreciation | 1.17M | 0.77M | 0.19M | 0.16M | 0.16M |
| Ebit | -5.24M | -8.97M | -7.61M | -4.44M | -2.68M |
| Ebitda | -4.07M | -8.19M | -7.42M | -4.28M | -2.52M |
| Depreciation and amortization | 1.17M | 0.77M | 0.19M | 0.16M | 0.16M |
| Operating income | -5.24M | -8.97M | -7.61M | -4.44M | -2.68M |
| Other operating expenses | 5.43M | 8.90M | 7.24M | 4.99M | 2.78M |
| Interest expense | 0.08M | 0.05M | 0.04M | 0.01M | 0.01M |
| Net interest income | -0.08M | -0.05M | -0.04M | -0.01M | -0.01M |
| Income tax expense | 0.08M | -0.74M | -1.02M | -0.10M | 0.01M |
| Total revenue | 0.19M | 0.73M | 0.69M | 0.67M | 0.10M |
| Total operating expenses | 5.37M | 8.69M | 7.14M | 4.70M | 2.76M |
| Cost of revenue | 0.05M | 0.21M | 0.10M | 0.29M | 0.01M |
| Total other income expense net | -11.06M | -0.80M | -1.10M | -0.43M | -0.03M |
| Net income from continuing ops | -16.38M | -9.03M | -7.69M | -4.77M | -2.71M |
| Net income applicable to common shares | -16.38M | -9.03M | -7.69M | -4.77M | -2.71M |
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Total assets | 1.08M | 12.30M | 3.47M | 4.90M | 1.68M |
| Intangible assets | - | 10.03M | 0.84M | 1.00M | 1.16M |
| Other current assets | 0.11M | 1.43M | 1.15M | 1.16M | - |
| Total liab | 3.41M | 2.42M | 2.08M | 1.20M | 0.56M |
| Total stockholder equity | -2.32M | 9.88M | 1.39M | 3.70M | 1.12M |
| Deferred long term liab | - | 0.11M | 0.25M | 0.13M | - |
| Other current liab | 0.05M | 0.14M | 0.18M | 0.35M | 0.17M |
| Common stock | 44.83M | 40.21M | 23.71M | 19.09M | 12.25M |
| Capital stock | 44.83M | 40.21M | 23.71M | 19.09M | - |
| Retained earnings | -50.66M | -34.17M | -25.14M | -17.45M | -12.67M |
| Other liab | - | 0.09M | - | - | - |
| Good will | - | - | - | 0.00M | 0.13M |
| Other assets | - | 0.12M | 0.57M | 0.14M | 0.00M |
| Cash | 0.85M | 0.12M | 0.23M | 2.16M | 0.18M |
| Total current liabilities | 3.37M | 2.29M | 2.04M | 1.20M | 0.56M |
| Current deferred revenue | 0.03M | 0.04M | 0.04M | 0.11M | 0.06M |
| Net debt | 0.05M | -0.04M | -0.12M | -2.16M | -0.18M |
| Short term debt | 0.86M | 0.04M | 0.07M | - | - |
| Short long term debt | 0.86M | - | 0.01M | - | - |
| Short long term debt total | 0.90M | 0.07M | 0.11M | - | - |
| Other stockholder equity | 3.51M | 3.83M | 2.82M | 2.05M | 0.12M |
| Property plant equipment | 0.00M | 0.05M | 0.12M | 0.01M | 0.01M |
| Total current assets | 1.08M | 2.10M | 1.94M | 3.75M | 0.38M |
| Net tangible assets | -2.32M | -0.15M | 0.55M | 2.70M | -0.16M |
| Net receivables | 0.12M | 0.29M | 0.30M | 0.30M | 0.20M |
| Long term debt | 0.04M | 0.03M | - | - | - |
| Inventory | 0.00M | 0.27M | 0.27M | 0.14M | - |
| Accounts payable | 2.43M | 2.08M | 1.85M | 0.74M | 0.33M |
| Accumulated other comprehensive income | - | 3.83M | 2.82M | 2.05M | 1.42M |
| Non currrent assets other | - | 0.12M | 0.57M | 0.14M | 0.00M |
| Non current assets total | 0.00M | 10.20M | 1.53M | 1.15M | 1.30M |
| Capital lease obligations | 0.00M | 0.04M | 0.10M | - | - |
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Investments | - | 0.00M | -0.02M | 0.00M | -0.01M |
| Change to liabilities | 0.38M | 0.44M | 0.94M | 0.40M | 0.26M |
| Total cashflows from investing activities | - | - | -0.02M | -0.02M | -0.01M |
| Net borrowings | 0.82M | -0.02M | -0.02M | -0.02M | -0.02M |
| Total cash from financing activities | 2.90M | 5.95M | 4.62M | 6.72M | 1.82M |
| Change to operating activities | 1.35M | 0.17M | -0.56M | -1.31M | 0.06M |
| Net income | -16.38M | -9.03M | -7.69M | -4.77M | -2.71M |
| Change in cash | 0.73M | -0.11M | -1.93M | 1.98M | -0.39M |
| Begin period cash flow | 0.12M | 0.23M | 2.16M | 0.18M | 0.57M |
| End period cash flow | 0.85M | 0.12M | 0.23M | 2.16M | 0.18M |
| Total cash from operating activities | -2.17M | -6.07M | -6.53M | -4.75M | -2.20M |
| Issuance of capital stock | 1.49M | 4.46M | 4.69M | 6.83M | - |
| Depreciation | 1.17M | 0.77M | 0.19M | 0.16M | 0.16M |
| Change to inventory | 0.05M | 0.20M | -0.16M | -0.14M | -0.14M |
| Change to account receivables | 0.13M | -0.11M | 0.02M | -0.02M | -0.03M |
| Other cashflows from financing activities | 1.46M | 1.57M | -0.04M | -0.11M | 0.09M |
| Change to netincome | 11.13M | 1.49M | 0.74M | 0.93M | 0.06M |
| Capital expenditures | 0.00M | 0.00M | 0.02M | 0.02M | 0.01M |
| Change in working capital | 1.91M | 0.70M | 0.24M | -1.07M | 0.29M |
| Stock based compensation | 0.07M | 1.14M | 0.74M | 0.62M | 0.05M |
| Other non cash items | 0.01M | 0.31M | 0.01M | 0.06M | 0.01M |
| Free cash flow | -2.17M | -6.07M | -6.54M | -4.75M | -2.20M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BNVIF Binovi Technologies Corp |
- -% |
0.00 | - | - | 0.07 | 0.08 | 0.29 | -0.06 |
| VEEV Veeva Systems Inc Class A |
-0.05 0.02% |
266.22 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
-6.60 5.03% |
124.50 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-5.60 9.39% |
54.01 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.07 1.31% |
5.28 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Binovi Technologies Corp. engages in the development, manufacturing, and commercialization of visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders in Canada, the United States, and internationally. The company's products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete's vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company's products under development includes Binovi Connect, a web-based video conferencing solution that connects consumers to vision care professionals. Binovi Technologies Corp. was formerly known as Eyecarrot Innovations Corp. and changed its name to Binovi Technologies Corp. in June 2020. The company was incorporated in 2011 and is based in Oakville, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Adam R. Cegielski B.Sc | Founder & Advisor | 1976 |
| Mr. Rakesh Malhotra B.Com., C.A., F.C.A., FCA (India), C.P.A., CPA, (U | CFO & Corp. Sec. | 1955 |
| Mr. Jatinder Dhaliwal | CEO, Interim CFO & Director | 1989 |
| Dr. Patrick Quaid | Chief Scientific Officer - Bv | 1979 |
| Mr. Joe Lia | Director of Video Production & Member of Advisory Board | NA |
| Dr. Robert Sanet | Special Advisor of Behavioral Optometry & Vision Training | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.